Literature DB >> 6947929

The different origin of primary and secondary chromosome aberrations in cancer.

G Levan, F Mitelman.   

Abstract

We have proposed a hypothetical model to explain the role of chromosomal aberrations in malignant development. In this model we postulate two kinds of chromosomal changes: (1) primary, active changes caused by direct interaction between the oncogenic agent and the hereditary material of the host cell. These changes are mainly somatic mutations, but may also be associated with directed structural changes visible in the microscope; and (2) secondary, passive changes arising randomly by nondisjunction and structural rearrangements. They are followed by selection of cells with changes that amplify the primary change and thus appear as nonrandom chromosome patterns. This hypothesis is discussed in the light of 1827 cases of human malignancy in which we have recently surveyed and systematized chromosomal aberrations. Special support for the idea of somatic mutations as the initiator of malignant development comes from work of Knudson and collaborators in human retinoblastoma. The Ph1 chromosome, predominant during the chronic phase of chronic myeloid leukemia (CML), is proposed as an instance of a primary change, whereas the chromosome changes during the blastic crisis of CML will illustrate the secondary changes. The most common of these secondary changes is actually the doubling of the Ph1 and thus an amplification of the primary change. The increase in number of copies of a specific chromosome reported by Green and collaborators demonstrates that this kind of amplification can result in direct response to the need for a specific gene located in that chromosome.

Entities:  

Mesh:

Year:  1981        PMID: 6947929     DOI: 10.1007/978-3-642-67984-1_26

Source DB:  PubMed          Journal:  Haematol Blood Transfus        ISSN: 0171-7111


  2 in total

Review 1.  An approach to oncological genetics.

Authors:  P Tautu; G Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 2.  Karyotypic progression in human tumors.

Authors:  S R Wolman
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.